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Abstract	  
Objective:	  We	  investigate	  the	  joint	  observation	  between	  type	  2	  diabetes	  and	  headache	  using	  
a	  case-­‐control	  study	  of	  a	  US	  ambulatory	  dataset.	  	  
Background:	  Recent	  whole-­‐population	  cohort	  studies	  propose	  that	  type	  2	  diabetes	  may	  have	  
a	  protective	  effect	  against	  headache	  prevalence.	  With	  headaches	  ranked	  as	  a	  leading	  cause	  
of	   disability,	   headache-­‐associated	   comorbidities	   could	   help	   identify	   shared	   molecular	  
mechanisms.	  
Methods:	  We	  performed	  a	  case-­‐control	  study	  using	  the	  US	  National	  Ambulatory	  Medical	  Care	  
Survey,	  2009,	  on	  the	  joint	  observation	  between	  headache	  and	  specific	  comorbidities,	  namely	  
type	  2	  diabetes,	  hypertension	  and	  anxiety,	  for	  all	  patients	  between	  18	  and	  65	  years	  of	  age.	  
The	  odds	   ratio	  of	  having	  a	  headache	  and	  a	   comorbidity	  were	  calculated	  using	  conditional	  
logistic	   regression,	   controlling	   for	   gender	   and	   age	   over	   a	   study	   population	   of	   3,327,947	  
electronic	  health	  records	  in	  the	  absence	  of	  prescription	  medication	  data.	  	  
Results:	  We	  observed	  estimated	  odds	  ratio	  of	  0.89	  (95%	  CI:	  0.83-­‐0.95)	  of	  having	  a	  headache	  
and	  a	  record	  of	  type	  2	  diabetes	  over	  the	  population,	  and	  0.83	  (95%	  CI:	  2.02-­‐2.57)	  and	  0.89	  
(95%	  CI:	  3.00-­‐3.49)	  for	  male	  and	  female,	  respectively.	  	  	  
Conclusions:	  We	  find	  that	  patients	  with	  type	  2	  diabetes	  are	  less	  likely	  to	  present	  a	  recorded	  
headache	   indication.	   Patients	   with	   hypertension	   are	   almost	   twice	   as	   likely	   of	   having	   a	  
headache	  indication	  and	  patients	  with	  an	  anxiety	  disorder	  are	  almost	  three	  times	  as	  likely.	  
Given	   the	   possibility	   of	   confounding	   indications	   and	   prescribed	   medications,	   additional	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Introduction	  
Headache,	  including	  tension-­‐type	  headaches,	  migraine	  and	  medication	  overuse	  headaches,	  
is	  the	  most	  common	  neurological	  disorder1.	  The	  percentage	  of	  the	  adult	  population	  with	  an	  
active	  headache	  disorder	  is	  as	  much	  as	  47	  %	  for	  a	  headache	  in	  general,	  10	  %	  for	  migraine,	  
38%	   for	   tension-­‐type	   headache,	   and	   3	   %	   for	   chronic	   headache2.	   With	   the	  World	   Health	  
Organization	  ranking	  migraine	  among	  the	  top	  causes	  of	  years	  of	  healthy	  life	  lost	  to	  disability3,	  
there	  is	  an	  unmet	  medical	  need	  for	  therapeutic	  intervention.	  	  However,	  our	  understanding	  of	  
what	  causes	  a	  headache	  and	  the	  association	  between	  specific	  comorbidities	  and	  headache	  
prevalence	  remains	  unclear.	  	  	  
The	   positively-­‐correlated	   association	   between	   hypertension	   disorders4-­‐8	   and	  
psychiatric	  disorders9-­‐13,	   such	  as	  depression	  and	  anxiety,	  has	  been	   long	  established	   in	   the	  
literature.	   	   Other	   co-­‐morbidities	   influencing	   headache	   incidence	   or	   severity	   have	   been	  
reported	  although	  the	  evidence	  for	  association	  with	  headache	  has	  been	  less	  robust.	  Diabetes	  
for	   example	   has	   been	   suggested	   to	   have	   a	   protective	   effect14-­‐17	   although	   whether	   the	  
association	  between	  headache	  and	  type	  2	  diabetes	  remains	  unclear	  and	  whether	  reported	  
effects	  are	  due	  to	  overlapping	  molecular	  mechanisms	  or	  to	  off-­‐target	  pharmacological	  effects	  
of	  diabetes	  treatment	  is	  equally	  unknown.	  A	  possible	  role	  for	  the	  insulin	  receptor	  in	  migraine	  
pathogenesis	   was	   suggested	   after	   five	   significant	   single	   nucleotide	   polymorphism	   (SNP)	  
variations	  were	  found	  over-­‐represented	  in	  the	  insulin	  receptor	  gene	  in	  migraine	  patients.	  This	  
association	  was	  independently	  replicated	  in	  a	  case-­‐control	  population	  collected	  separately	  14.	  	  
Other	   related	   observations	   include	   higher	   insulin	   levels,	   a	   condition	   associated	   with	  
prediabetes,	   in	  migraineurs	   than	   in	   controls	   and	  elevated	  blood-­‐glucose	   levels	   in	  patients	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with	  typical	  headache15.	  Furthermore,	  population-­‐based	  prospective	  studies	  have	  yielded	  a	  
significant	  association	  between	  a	  decreased	  risk	  of	  migraine	  with	  type	  2	  diabetes16,17.	  	  
Nonetheless,	  a	  number	  of	  published	  studies	  have	  not	  reported	  an	  apparent	  protective	  
effect	  of	  diabetes.	  A	  case-­‐control	  study	  examining	  insulin	  resistance	  in	  migraineurs	  did	  not	  
find	  a	  significant	  association	  with	  migraine,	  although	  the	  results	  remained	  inconclusive	  given	  
the	  small	  sample	  population	  and	  due	  to	  several	  patients	  with	  a	  low	  disease	  activity18.	  A	  cross-­‐
sectional	  study	  on	  chronic	  migraine	  prevalence	  in	  women	  suggests	  that	  chronic	  migraine	  is	  
actually	  positively	  associated	  with	   insulin	   resistance,	  particularly	  when	   in	  partnership	  with	  
obesity19.	  Yet,	  a	  different	  study	  on	  the	  prevalence	  of	  migraine	  in	  patients	  with	  type	  2	  diabetes	  
failed	  to	  find	  a	  positive	  association20.	  	  Finally,	  although	  a	  recent	  cross-­‐sectional	  population-­‐
based	   study	   also	   failed	   to	   identify	   an	   inverse	   relationship	   between	   type	   2	   diabetes	   and	  
headache,	  an	  association	  between	  type	  1	  diabetes	  and	  both	  headache	  (OR	  =	  0.55,	  95%	  CI	  
0.34-­‐0.88)	  and	  migraine	  (OR	  =	  0.47,	  95	  %	  CI	  0.26-­‐0.96)	  was	  found21.	  	  
Several	   abnormalities	   associated	   with	   insulin	   resistance	   have	   been	   reported	   in	  
patients	   with	   migraine22.	   Glucose	   plasma	   concentrations	   were	   significantly	   higher	   in	  
migraineurs	   with	   insulin	   sensitivity	   impaired	   in	   migraine22.	   Studies	   suggest	   that	   insulin	  
resistance	  is	  associated	  with	  migraine22	  and	  insulin	  resistance	  is	  also	  associated	  with	  type	  2	  
diabetes23.	  Patients	  with	  migraine	  frequently	  report	  that	  fasting,	  a	  condition	  where	  there	  is	  
an	   insulin	   receptor	   activation,	   is	   a	   trigger	   of	   headache	   attacks24	   whilst	   a	   separate	   study	  
revealed	  that	  a	  low-­‐sucrose	  diet	  may	  reduce	  the	  frequency	  of	  migraine	  attacks25.	  Clearly,	  the	  
relationship	  between	  headache	  and	  type	  2	  diabetes	  remains	  unresolved.	  
We	  sought	  to	  investigate	  the	  joint	  observation	  between	  type	  2	  diabetes	  and	  headache	  
using	  a	  case-­‐control	  study	  exploiting	  a	   large	  US	  ambulatory	  electronic	  health	  record	  (EHR)	  
dataset	   containing	   over	   6.5	  million	   records.	   The	   ICD-­‐9	   indication	   codes	   presented	   in	   the	  
.CC-BY-NC-ND 4.0 International licenseavailable under a
not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (which wasthis version posted June 4, 2018. ; https://doi.org/10.1101/336586doi: bioRxiv preprint 
	   5	  
dataset	   were	   grouped	   by	   the	   tested	   comorbidity	   indications,	   headache,	   type	   2	   diabetes,	  
anxiety	   and	   hypertension.	   To	   validate	   our	   method,	   we	   also	   examined	   the	   well-­‐studied	  
relationships	  between	  headache	  with	  hypertension	  and	  headache	  with	  anxiety.	  	  
	  
Methods	  
Data	   source:	  We	   calculate	   the	   odds	   ratio	   of	   a	   joint	   observation	   between	   headache	   and	  
specific	   comorbidities	   using	   data	   from	   The	  US	   National	   Ambulatory	  Medical	   Care	   Survey	  
(https://www.cdc.gov/nchs/ahcd/index.htm),	   2009.	   This	   is	   a	   cross	   sectional	   national	  
probability	   sample	   survey	   that	   sampled	   6,552,504	   subjects	   randomly.	   The	   survey	   was	  
conducted	  by	  the	  Division	  of	  Health	  Care	  Statistics,	  National	  Center	  for	  Health	  Statistics,	  and	  
the	  Centers	   for	  Disease	  Control	   and	  Prevention.	  As	  of	  2006,	  NAMCS	   includes	  a	   sample	  of	  
community	   health	   centers,	   using	   information	   from	   the	   Health	   Resources	   Service	  
Administration	   and	   the	   Indian	   Health	   Service.	   Demographic	   information	   from	   these	  
participants	  include	  sex,	  race,	  patient	  age	  in	  years,	  year	  surveyed,	  and	  up	  to	  seven	  ICD-­‐9	  code	  
entries	  for	  disease.	  Public	  use	  datasets	  and	  instruction	  files	  related	  to	  this	  study	  can	  be	  found	  
at	  https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm.	  
	  
Study	  population:	  The	  US	  NAMCS	  dataset	  was	  reduced	  to	  a	  study	  population	  of	  5,661,688.	  
The	  sample	  population	  was	   restricted	  by	  age	   (18	   to	  65	  years	   in	  age,	   inclusive),	   required	  a	  
gender	  entry,	  and	  at	  least	  one	  valid	  medical	  indication.	  Records	  with	  an	  indication	  from	  the	  
ICD-­‐9	   groups	   “8[0-­‐9][0-­‐9]”	   or	   “9[0-­‐9][0-­‐9]”,	   which	   could	   link	   a	   headache	   to	   a	   secondary	  
indication	  of	  injury	  or	  poisoning	  were	  removed.	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Exposure:	  We	  defined	  a	  headache	  indication	  as	  any	  record	  from	  the	  study	  population	  with	  an	  
ICD-­‐9	  code	  from	  the	  groups	  339.*,	  784.0*	  and	  307.81.	  These	  grouped	  codes	  represent;	  other	  
headache	   syndrome,	   including	   cluster	   headache	   and	   tension	   headache;	   headache	  
characterized	  by	  a	  sensation	  of	  marked	  discomfort	  in	  various	  parts	  of	  the	  head	  and	  neck;	  and	  
tension	  headache	  specifically	  related	  to	  psychological	  factors,	  respectively.	  	  We	  defined	  a	  type	  
2	  diabetes	  indication	  as	  any	  record	  from	  the	  study	  population	  with	  an	  ICD-­‐9	  code	  of	  either	  
250.00	   or	   250.02.	   All	   indications	   of	   anxiety,	   dissociative	   and	   somatoform	   disorder	   were	  
defined	  by	  the	  ICD-­‐9	  code	  group	  300.*,	  and	  collectively	  referred	  to	  as	  anxiety	  disorders	  for	  
the	  purpose	  of	  this	  study.	  We	  defined	  a	  hypertension	  indication	  as	  any	  records	  from	  the	  study	  
population	  with	  an	  ICD-­‐9	  code	  from	  the	  group	  401.*;	  these	  codes	  include	  malignant	  essential	  
hypertension,	  benign	  essential	  hypertension	  and	  unspecified	  essential	  hypertension.	  	  
	  
Statistical	   Analysis:	   We	   perform	   a	   case-­‐control	   study	   to	   analyze	   the	   joint	   observation	  
between	  each	  of	  the	  three	  conditions,	  namely	  anxiety,	  hypertension	  and	  type	  2	  diabetes,	  with	  
a	   headache	   indication.	   The	   prevalence	   of	   each	   condition	   alone	   and	   each	   condition	  
accompanied	  by	  a	  headache	  indication	  was	  calculated	  over	  the	  study	  population	  and	  then	  
controlling	  for	  gender.	  Conditional	   logistic	  regression	  (CLR)	  with	  a	  95%	  confidence	   interval	  
(CI)	  was	  used	   to	  estimate	  an	  odds	   ratio	   (OR)	  of	  disease	  observation	  by	  matching	  age	  and	  
gender	  for	  two	  controls	  (absence	  of	  headache)	  per	  case	  of	  headache	   indication.	  Male	  and	  
female	   specific	   disease	   observations	   were	   calculated	   separately.	   A	   P-­‐value	   <	   0.01	   was	  
considered	   statistically	   significant.	   Statistical	   analyses	   were	   performing	   using	   R	   software	  
version	  3.4.3.	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Results	  
Identification	  of	  diseases.	  
Disease	   indications	   were	   grouped	   by	   their	   ICD-­‐9	   codes	   (Table	   1).	   Headache	   codes	   were	  
collected	  using	  the	  classification	  for	  a	  tension	  headache	  and	  general	  diagnosis	  for	  headache.	  
Instances	  of	  cluster	  headache	  were	  excluded	  due	  to	   their	   infrequency	  within	   the	  sampled	  
population.	  The	  grouped	  anxiety	  indications	  were	  collected	  using	  the	  ICD-­‐9	  tree	  from	  EHRs	  
that	   matched	   the	   regular	   expression	   300.*.	   These	   codes	   included	   indication	   for	   anxiety,	  
phobias,	   dissociative	   disorders	   and	   somatization	   disorders.	   The	   grouped	   hypertension	  
indications	  were	  matched	  using	  the	  regular	  expression	  401.*.	  Only	  three	  hypertension	  ICD-­‐9	  
codes,	  malignant,	  benign	  and	  unspecified,	  were	  present.	  	  The	  ICD-­‐9	  codes	  for	  type	  2	  diabetes	  
were	  picked	  specifically	  to	  include	  indications	  for	  type	  2	  diabetes	  without	  a	  mention	  of	  further	  
complication.	  	  
	  
Disease	  prevalence	  and	  demographic	  data.	  In	  this	  study,	  we	  identified	  3,327,947	  EHRs	  that	  
met	  our	  inclusion	  criteria,	  of	  which	  1,130,505	  were	  male	  and	  2,197,442	  were	  female.	  A	  t-­‐test	  
performed	  between	  the	  age	  of	  males	  to	  females	  was	  found	  to	  be	  insignificant	  (Table	  2	  for	  age	  
calculations	  stratified	  by	  gender).	  We	  observed	  a	  male	  and	  female	  combined	  mean	  age	  of	  
41.2	   (+/-­‐	   12.3)	   years	   for	   records	  with	   an	   indication	  of	   headache,	   43.2	   (+/-­‐	   12.6)	   years	   for	  
anxiety,	  a	  decade	  later	  at	  52.2	  (+/-­‐	  9.5)	  years	  for	  records	  with	  hypertension,	  and	  52.9	  (+/-­‐	  9.9)	  
years	  for	  type	  2	  diabetes.	  We	  also	  observed	  a	  mean	  age	  of	  41.6	  (+/-­‐	  11.8)	  years	  for	  headache	  
with	  an	  anxiety	  disorder,	  46.6	  (+/-­‐	  10.3)	  years	  for	  a	  headache	  with	  a	  hypertension	  disorder,	  
and	  49.7	  (+/-­‐	  10.0)	  years	  for	  headache	  and	  type	  2	  diabetes.	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The	   joint	   observation	   between	   disease	   and	   headache.	   The	   estimated	   OR	   for	   a	   risk	   of	  
headache	  in	  records	  with	  an	  indication	  of	  anxiety	  disorder,	  hypertension,	  or	  type	  2	  diabetes	  
was	  calculated	  using	  conditional	   logistic	  regression	  with	  a	  95	  %	  CI	  (Table	  3).	  For	  each	  case	  
(tested	   comorbidity	   with	   headache	   indication)	   two	   controls	   (disease	   with	   no	   headache	  
indication)	   were	   randomly	   identified	   from	   the	   sample	   population,	   matched	   by	   age	   and	  
gender,	  followed	  by	  two	  additional	  CLR	  calculations	  over	  each	  gender	  cohort	  whilst	  matching	  
for	  age	  only.	  We	  observed	  an	  increased	  estimate	  of	  joint	  observation	  between	  those	  records	  
with	  anxiety	  (OR	  =	  2.87	  95%	  CI:	  2.70-­‐3.06)	  or	  hypertension	  (OR	  =	  1.86	  95%	  CI:	  1.79-­‐1.93)	  and	  
a	  headache	  indication.	  We	  observed	  a	  greater	  estimate	  in	  OR	  in	  both	  tested	  comorbidities,	  
anxiety	  and	  hypertension,	  in	  the	  female	  cohort	  compared	  with	  the	  male	  cohort	  (OR	  Males	  
2.28	  95%	  CI:	  2.02	  –	  2.57,	  1.64	  95%	  CI:	  1.54	  –	  1.76;	  OR	  Females	  3.24	  95%	  CI:	  3.00	  –	  3.49,	  1.95%	  
CI:	  1.87	  –	  2.05,	  respectively).	  	  
By	  contrast,	  we	  observed	  a	  drop	  in	  OR	  between	  those	  records	  with	  an	  indication	  for	  
type	  2	  diabetes	  and	  an	   indication	   for	  headache	   (OR	  =	  0.89	  95%	  CI:	  0.83-­‐0.95),	  with	  males	  
having	  lower	  estimated	  odds	  (0.83	  95%	  CI:	  0.75-­‐0.93)	  than	  females	  (0.89	  95%	  CI:	  0.83-­‐0.96).	  
All	  estimated	  ORs	  were	  statistically	  significant	  (p	  <	  0.01).	  	  
	  
Conclusions	  
This	  case-­‐control	  study	  of	  a	  large	  US	  EHR	  dataset	  presents	  results	  that	  suggest	  type	  2	  diabetes	  
has	  a	  protective	  association	  on	  headache	  prevalence	  in	  male	  and	  female	  cohorts	  between	  18	  
and	  65	  years	  of	  age.	  Our	  findings	  of	  a	  joint	  observation	  between	  headache	  and	  hypertension	  
and	  anxiety	  disorders	  demonstrates	  that	  this	  dataset	  is	  in	  agreement	  with	  existing	  literature,	  
validating	  our	  methodology.	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   Earlier	   accounts	   of	   an	   association	   between	   diabetes	   and	   headache	   have	   been	  
reported14-­‐25,	   however,	  we	   present	   a	   new	   case-­‐control	   study	   using	   an	   ambulatory	   survey	  
curated	  with	  over	  thirty	  years	  of	  patient	  cases	  across	  an	  extensive	  and	  diverse	  population.	  	  
This	   study	   takes	   no	   account	   for	   some	   of	   the	   confounds	   or	   other	   concerns	   of	  
conventional	   epidemiology.	   Specifically;	   there	  are	   fewer	   indications	  per	   record	  during	   the	  
first	  surveyed	  year	  (1979),	  suggesting	  potential	  unclassified	  cases;	  it	  is	  not	  possible	  to	  be	  sure	  
whether	  the	  observed	  tested	  co-­‐morbidity	  (anxiety,	  hypertension,	  type	  2	  diabetes)	  is	  due	  to	  
the	  disease	  itself	  or	  any	  prescribed	  medications;	  statistical	  analysis	  over	  explicit	  indication	  for	  
migraine	  does	  not	  have	   statistical	  power;	  and,	   finally,	   there	  exists	  outdated	  diagnoses	   for	  
vascular	  headache,	  which	  is	  considered	  as	  an	  outdated	  term	  and	  a	  misdiagnosis.	  Despite	  the	  
limitations	  of	  deriving	  knowledge	  from	  data	  using	  this	  approach,	  the	  fact	  that	  our	  findings	  for	  
the	  odds	  ratio	  of	  observing	  headache	  with	  an	  indication	  for	  either	  anxiety	  of	  hypertension	  
replicate	  earlier	  studies	  offers	  strong	  support	  to	  our	  results.	  Further	  population	  based	  studies	  
taking	  into	  account	  prescribed	  medications	  would	  be	  the	  first	  step	  in	  separating	  physiological	  
effect	  from	  pharmacological	  effect.	   Insights	  into	  the	  etiological	  overlap	  between	  headache	  
and	  type	  2	  diabetes	  might	  be	  revealed	  from	  common	  genetic	  associations	  between	  the	  two	  
disorders	  within	  large,	  well	  phenotyped	  and	  genotyped	  cohorts	  such	  as	  the	  UK	  Biobank.	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ICD	  9	  Code	   Description	  
Headache	   	  
307.81	   Tension	  headache	  
784.0	   Headache	  
Anxiety	   	  
300.00	   Anxiety,	  dissociative	  and	  somatoform	  disorders	  
300.01	   Panic	  disorder,	  with	  agoraphobia	  
300.10	   Hysteria,	  unspecified	  
300.11	   Conversion	  disorder	  
300.12	   Dissociative	  amnesia	  
300.15	   Dissociative	  disorder	  or	  reaction,	  unspecified	  
300.16	   Factitious	  disorder	  with	  predominantly	  psychological	  signs	  and	  symptoms	  
300.20	   Phobia,	  unspecified	  
300.29	   Other	  isolated	  or	  specific	  disorders	  
300.3	   Obsessive-­‐compulsive	  disorders	  
300.4	   Dysthymic	  disorder	  
300.5	   Neurasthenia	  
300.7	   Hypochondriasis	  
300.81	   Somatization	  disorder	  
300.89	   Other	  somatoform	  disorders	  
300.9	   Unspecified	  nonpsychotic	  mental	  disorder	  
300.02	   Generalized	  anxiety	  disorder	  
300.13	   Dissociative	  fugue	  
300.14	   Dissociative	  identity	  disorder	  
300.21	   Agoraphobia	  with	  panic	  disorder	  
300.09	   Other	  anxiety	  states	  
300.22	   Agoraphobia	  without	  mention	  of	  panic	  attack	  
300.6	   Depersonalization	  disorder	  
300.19	   Other	  and	  unspecified	  factitious	  illness	  
300.23	   Social	  phobia	  
300.82	   Undifferentiated	  somatoform	  disorder	  
Hypertension	   	  
401.0	   Malignant	  essential	  hypertension	  
401.1	   Benign	  essential	  hypertension	  
401.9	   Unspecified	  essential	  hypertension	  
Type	  II	  diabetes	   	  
250.00	   Diabetes	  mellitus	  without	  mention	  of	  complication,	  type	  II	  or	  unspecified	  type,	  not	  
stated.	  
250.02	   Diabetes	  mellitus	  without	  mention	  of	  complication,	  type	  II	  or	  unspecified	  type,	  
uncontrolled.	  
	  
Table	  1.	  ICD-­‐9	  drug	  codes	  for	  indications	  pertaining	  to	  headache,	  anxiety,	  hypertension	  and	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Headache	   	   	   	  
Count	   23,172(0.70%)	   7,189	  (0.64%)	   15,983	  (0.73%)	  
Age	   41.2	  (12.3)	   41.7	  (12.3)	   40.3	  (12.4)	  
Anxiety	  disorders	   	   	   	  
Count	   89,757	  (2.70%)	   31,345	  (2.77%)	   58,412	  (2.66%)	  
Age	   43.2	  (12.6)	   42.6	  (12.5)	   43.5	  (12.7)	  
Hypertension	  disorders	   	   	   	  
Count	   407,508	  (12.25%)	   198,327	  (17.45%)	   209,181	  (9.52%)	  
Age	   52.6	  (9.5)	   52.6	  (9.4)	   52.7	  (9.6)	  
Type	  2	  diabetes	   	   	   	  
Count	   170,156	  (5.11%)	   79,929	  (7.07%)	   90,227	  (4.11%)	  
Age	   52.9	  (9.9)	   53.6	  (9.0)	   52.3	  (10.5)	  
Headache	  and	  anxiety	  
disorders	  
	   	   	  
Count	   2030	   485	   1545	  
Age	   41.6	  (11.8)	   41.8	  (11.7)	   41.6	  (11.8)	  
Headache	  and	  hypertension	  
disorders	  
	   	   	  
Count	   4605	   1524	   2081	  
Age	   48.6	  (10.3)	   47.8	  (10.4)	   49.0	  (10.2)	  
Headache	  and	  type	  2	  
diabetes	  
	   	   	  
Count	   1068	   349	   719	  
Age	   49.7	  (10.0)	   50.0	  (9.8)	   49.6	  (10.1)	  
	  
Table	  2.	  The	  distribution	  and	  mean	  age	  (with	  standard	  deviation)	  of	  each	  of	  the	  four	  
indications	  across	  the	  study	  population	  and	  stratified	  by	  gender,	  followed	  by	  indications	  




	   Population	   Male	   Female	  
Anxiety	  disorders	   2.87	  (2.70-­‐3.06)**	   2.28	  (2.02-­‐2.57)**	   3.24	  (3.00-­‐3.49)**	  
Hypertension	  disorder	   1.86	  (1.79-­‐1.93)**	   1.64	  (1.54-­‐1.76)**	   1.95	  (1.87-­‐2.05)**	  
Type	  2	  diabetes	   0.89	  (0.83-­‐0.95)**	   0.83	  (0.75-­‐0.93)**	   0.89	  (0.83-­‐0.96)*	  
	  
Table	  3.	  The	  OR	  (95%	  CI)	  of	  each	  disorder	  in	  association	  with	  a	  headache	  indication,	  over	  
the	  whole	  population	  matched	  for	  age	  and	  gender,	  and	  then	  matched	  for	  age	  and	  stratified	  
by	  gender.	  **	  p	  <	  0.001	  and	  *	  p	  <	  0.01	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